Implementing novel CRISPR screening models to inform HIV cure strategies by characterizing primary human CD4 T cell resistance to CD8 cytotoxicity
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
Project Abstract: Significant advances in antiretroviral therapy (ART) has enabled functional suppression of HIV, allowing individual individuals on ART to live relatively normal lives. However, viral rebound from a persistent reservoir of provirus-harboring cells following ART cessation demands a lifelong reliance on ART. ART-free control of this persistent reservoir therefore represents the current focus of HIV cure strategies. Recent work from our group and others has identified HIV-infected CD4 T cells that exhibit cell-intrinsic resistance to CD8 cytotoxicity, despite antigen expression and recognition. While identification of resistance factors previously annotated in cancer (such as overexpression of the granzyme inhibitor SERPINB9 and the anti-apoptotic protein BCL-2) has provided some insight concerning underlying mechanisms, the factors leading to this resistance phenotype remain largely unknown. To address this, we have developed a novel genome-wide screening platform that allows identification of genes involved in primary human CD4 T cell resistance and susceptibility to CD8 T cell cytotoxicity. In this proposal, we aim to maximize the potential of this newly developed CD4 resistance screening model (CRSM). Additional screens in different contexts will be conducted to further enrich the dataset. We will also employ a methodical pipeline for hit validation and therapeutic characterization. This pipeline will begin with promising hits identified in the initial screen, including the lipid metabolism-associated PPAR family proteins. This proposal will produce a robust functional genomic dataset thoroughly characterizing the mechanisms underlying CD4 resistance to CD8 killing. With these datasets, we envision the nomination of a range of promising targets for small-molecule sensitization of HIV-infected CD4s to CD8 killing.
Grant Summary
Implementing novel CRISPR screening models to inform HIV cure strategies by characterizing primary human CD4 T cell resistance to CD8 cytotoxicity is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $50K for university, nonprofit, healthcare org. Applications are due 2029-03-31 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $50K
2029-03-31
- 1Confirm your organization is eligible for Implementing novel CRISPR screening models to inform HIV cure strategies by characterizing primary human CD4 T cell resistance to CD8 cytotoxicity from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Implementing novel CRISPR screening models to inform HIV cure strategies by characterizing primary human CD4 T cell resistance to CD8 cytotoxicity: Frequently Asked Questions
Who is eligible for the Implementing novel CRISPR screening models to inform HIV cure strategies by characterizing primary human CD4 T cell resistance to CD8 cytotoxicity?
Implementing novel CRISPR screening models to inform HIV cure strategies by characterizing primary human CD4 T cell resistance to CD8 cytotoxicity is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Implementing novel CRISPR screening models to inform HIV cure strategies by characterizing primary human CD4 T cell resistance to CD8 cytotoxicity provide?
Implementing novel CRISPR screening models to inform HIV cure strategies by characterizing primary human CD4 T cell resistance to CD8 cytotoxicity provides up to $50K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Implementing novel CRISPR screening models to inform HIV cure strategies by characterizing primary human CD4 T cell resistance to CD8 cytotoxicity deadline?
Applications for Implementing novel CRISPR screening models to inform HIV cure strategies by characterizing primary human CD4 T cell resistance to CD8 cytotoxicity are due 2029-03-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Implementing novel CRISPR screening models to inform HIV cure strategies by characterizing primary human CD4 T cell resistance to CD8 cytotoxicity?
To apply for Implementing novel CRISPR screening models to inform HIV cure strategies by characterizing primary human CD4 T cell resistance to CD8 cytotoxicity, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.